CN Patent

CN106029073A — 治疗具有ros1突变型癌细胞的患者的化合物

Assigned to Nerviano Medical Sciences SRL · Expires 2016-10-12 · 10y expired

What this patent protects

本文公开了如说明书中所定义的式(I)或者式2.(I)的经取代的吲唑衍生物及其药学上可接受的盐、它们的制备方法以及包含它们的药物组合物；本发明的化合物可以用于治疗与失调的蛋白激酶活性相关的疾病(例如，癌症)的治疗中。

USPTO Abstract

本文公开了如说明书中所定义的式(I)或者式2.(I)的经取代的吲唑衍生物及其药学上可接受的盐、它们的制备方法以及包含它们的药物组合物；本发明的化合物可以用于治疗与失调的蛋白激酶活性相关的疾病(例如，癌症)的治疗中。

Drugs covered by this patent

Patent Metadata

Patent number
CN106029073A
Jurisdiction
CN
Classification
—
Expires
2016-10-12
Drug substance claim
No
Drug product claim
No
Assignee
Nerviano Medical Sciences SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.